Mylan launches Remdesivir at Rs 4,800 for Covid patients in India

The company has also launched a 24x7 helpline using which patients and healthcare practitioners can access information about the drug and its availability

In order to meet the growing demand of life-saving drug remdesivir to treat Covid-19 patients, US headquartered pharmaceutical company Mylan has launched the product under the brand name Desrem.

The company has also launched a 24x7 helpline where patients and healthcare practitioners can access information about the drug and its availability.

Priced at Rs 4,800 per vial, the drug will be manufactured at the company’s state-of-the-art injectable facility in Bengaluru, which will work to service the demand in India and other export markets where Mylan has received a licence from Gilead for the commercialisation of remdesivir. 

“In the wake of increasing cases of